XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of segment revenues and profit

Segment revenues and profits were as follows:

			Three Months Ended September 30,												Nine Months Ended September 30,
(in millions)			2022						2021						2022						2021
Revenues:
Salix			$	544					$	527					$	1,509					$	1,515
International			250						271						727						890
Solta Medical			72						74						201						219
Diversified Products			238						290						722						850
Bausch + Lomb			942						949						2,772						2,764
			$	2,046					$	2,111					$	5,931					$	6,238
Segment profits:
Salix			$	391					$	377					$	1,067					$	1,074
International			85						92						242						304
Solta Medical			33						40						88						120
Diversified Products			151						185						450						547
Bausch + Lomb			226						247						640						699
			886						941						2,487						2,744
Corporate			(218)						(186)						(614)						(566)
Amortization of intangible assets			(290)						(338)						(902)						(1,055)
Goodwill impairments			(119)						—						(202)						(469)
Asset impairments, including loss on assets held for sale			(1)						(18)						(15)						(213)
Restructuring, integration, separation and IPO costs			(10)						(8)						(58)						(29)
Other income (expense), net			(4)						183						(6)						(329)
Operating income			244						574						690						83
Interest income			3						2						8						6
Interest expense			(385)						(351)						(1,157)						(1,083)
Gain (loss) on extinguishment of debt			570						(12)						683						(62)
Foreign exchange and other			7						3						4						11
Income (loss) before income taxes			$	439					$	216					$	228					$	(1,045)

Schedule of revenues by segment and product category

Revenues by segment and product category were as follows:

(in millions)			Salix						International						Solta Medical						Diversified Products						Bausch + Lomb						Total
			Three Months Ended September 30, 2022
Pharmaceuticals			$	543					$	72					$	—					$	206					$	121					$	942
Devices			—						—						72						—						390						462
OTC			—						38						—						2						362						402
Branded and Other Generics			—						131						—						24						65						220
Other revenues			1						9						—						6						4						20
			$	544					$	250					$	72					$	238					$	942					$	2,046
			Three Months Ended September 30, 2021
Pharmaceuticals			$	525					$	61					$	—					$	234					$	121					$	941
Devices			—						—						74						—						395						469
OTC			—						41						—						3						365						409
Branded and Other Generics			—						161						—						47						61						269
Other revenues			2						8						—						6						7						23
			$	527					$	271					$	74					$	290					$	949					$	2,111
			Nine Months Ended September 30, 2022
Pharmaceuticals			$	1,508					$	206					$	—					$	608					$	348					$	2,670
Devices			—						—						201						—						1,168						1,369
OTC			—						111						—						5						1,061						1,177
Branded and Other Generics			—						386						—						91						178						655
Other revenues			1						24												18						17						60
			$	1,509					$	727					$	201					$	722					$	2,772					$	5,931
			Nine Months Ended September 30, 2021
Pharmaceuticals			$	1,509					$	187					$	—					$	699					$	380					$	2,775
Devices			—						—						219						—						1,174						1,393
OTC			—						98						—						7						1,010						1,115
Branded and Other Generics			—						579						—						125						180						884
Other revenues			6						26						—						19						20						71
			$	1,515					$	890					$	219					$	850					$	2,764					$	6,238

Schedule of revenue attributed to a geographic region

Revenues are attributed to a geographic region based on the location of the customer and were as follows:

			Three Months Ended September 30,												Nine Months Ended September 30,
(in millions)			2022						2021						2022						2021
U.S. and Puerto Rico			$	1,219					$	1,251					$	3,524					$	3,629
China			116						121						293						350
Canada			92						84						258						247
Poland			65						70						204						203
Mexico			70						66						200						191
France			44						50						159						160
Japan			47						57						148						172
Germany			55						64						112						116
United Kingdom			22						19						85						83
Russia			42						36						122						106
Spain			17						20						61						62
Italy			17						20						60						58
South Korea			19						18						58						58
Other			221						235						647						803
			$	2,046					$	2,111					$	5,931					$	6,238

Schedule of customers that accounted for 10% or more of total revenue

Customers that accounted for 10% or more of total revenues were as follows:

			Nine Months Ended September 30,
			2022						2021
AmerisourceBergen Corporation			16%						18%
McKesson Corporation (including McKesson Specialty)			13%						16%
Cardinal Health, Inc.			11%						12%

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration